MRNA vs JNJ vs PFE vs ABT

For growth investors, Abbott Laboratories (ABT) is the stronger pick with 4.

6% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

4x versus Johnson & Johnson at 39. 0x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 52x versus Johnson & Johnson's 34. 64x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +49.

2%, compared to -71. 3% for Moderna, Inc. (MRNA). Over 10 years, the gap is even starker: ABT returned +171. 8% versus PFE's +30. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Moderna, Inc. 's 1. 82β — meaning MRNA is approximately 3087% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Moderna, Inc. (MRNA) carries a lower debt/equity ratio of 22% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Abbott Laboratories (ABT) is pulling ahead at 4.

6% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, JNJ leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 52x versus Johnson & Johnson's 34. 64x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 19. 5x for Johnson & Johnson — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABT: 47. 6% to $128. 71.

In this comparison, PFE (6.

5% yield), ABT (2. 5% yield), JNJ (2. 2% yield) pay a dividend. MRNA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 8% 10Y return). Moderna, Inc. (MRNA) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +136. 8%, MRNA: +151. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MRNA is a mid-cap quality compounder stock; JNJ is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; ABT is a mid-cap deep-value stock. JNJ, PFE, ABT pay a dividend while MRNA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.